Johnson & Johnson agrees to $6.5 billion payout for talc cancer claims

Johnson & Johnson will pay $6.5 billion to settle nearly all talc ovarian cancer lawsuits in the U.S. — a deal, pending approval from plaintiffs, that would allow J&J to resolve lawsuits through a third bankruptcy filing of a subsidiary

Johnson & Johnson is set to pay out $6.5 billion to settle the majority of legal cases filed by women who developed ovarian tumors linked to the use of talcum powder-based products. This settlement covers 99.75% of the total litigation, while the remaining cases, which involve mesothelioma, will be handled outside of this new resolution plan. The current agreement is closely tied to a third bankruptcy declaration by a subsidiary company.

These cancer cases have reportedly caused decades of financial and public relations issues for J&J, which has consistently maintained that its now-discontinued baby talc, along with other talcum powder products, are safe for consumer use (approximately 99% of talc-related lawsuits against J&J and its subsidiaries stem from ovarian cancer).

Pending approval from the claimants, the agreement would allow J&J to resolve the lawsuits through a third bankruptcy declaration by its subsidiary, LTL Management. Courts have rejected two previous attempts by J&J to settle the lawsuits through the bankruptcy of this subsidiary, which was created to absorb the company’s liabilities in the talc sector.

The article draws upon studies published and recommendations from international institutions and/or experts. We do not make claims in the medical-scientific field and report the facts as they are. Sources are indicated at the end of each article.
Condividi su Whatsapp Condividi su Linkedin